Cognitive performance is related to cortical grey matter volumes in early stages of schizophrenia: A population-based study of first-episode psychosis

BackgroundSome neuroimaging studies have supported the hypothesis of progressive brain changes after a first episode of psychosis. We aimed to determine whether (i) first-episode psychosis patients would exhibit more pronounced brain volumetric changes than controls over time and (ii) illness course/treatment would relate to those changes.MethodLongitudinal regional grey matter volume and ventricle:brain ratio differences between 39 patients with first-episode psychosis (including schizophrenia and schizophreniform disorder) and 52 non-psychotic controls enrolled in a population-based case-control study.ResultsWhile there was no longitudinal difference in ventricle:brain ratios between first-episode psychosis subjects and controls, patients exhibited grey matter volume changes, indicating a reversible course in the superior temporal cortex and hippocampus compared with controls. A remitting course was related to reversal of baseline temporal grey matter deficits.ConclusionsOur findings do not support the hypothesis of brain changes indicating a progressive course in the initial phase of psychosis. Rather, some brain volume abnormalities may be reversible, possibly associated with a better illness course.

Download Full-text

Catatonia is associated with worse cognitive performance in patients with first-episode psychosis antipsychotic-naive: a 3-month follow-up study

10.26226/morressier.5971be84d462b80290b5267b ◽

2017 ◽

Author(s):

Jorge Cuevas Esteban

Keyword(s):

Cognitive Performance ◽

First Episode Psychosis ◽

First Episode ◽

Follow Up Study ◽

Episode Psychosis

Download Full-text

Estimating the incidence of first-episode psychosis using population-based health administrative data to inform early psychosis intervention services

Psychological Medicine ◽

10.1017/s0033291718002933 ◽

2018 ◽

Vol 49 (12) ◽

pp. 2091-2099 ◽

Cited By ~ 8

Author(s):

Kelly K. Anderson ◽

Ross Norman ◽

Arlene G. MacDougall ◽

Jordan Edwards ◽

Lena Palaniyappan ◽

...

Keyword(s):

Psychotic Disorder ◽

Administrative Data ◽

Catchment Area ◽

Population Based ◽

First Episode Psychosis ◽

Case Definition ◽

First Episode ◽

Affective Psychosis ◽

Health Administrative Data ◽

Episode Psychosis

AbstractBackgroundDiscrepancies between population-based estimates of the incidence of psychotic disorder and the treated incidence reported by early psychosis intervention (EPI) programs suggest additional cases may be receiving services elsewhere in the health system. Our objective was to estimate the incidence of non-affective psychotic disorder in the catchment area of an EPI program, and compare this to EPI-treated incidence estimates.MethodsWe constructed a retrospective cohort (1997–2015) of incident cases of non-affective psychosis aged 16–50 years in an EPI program catchment using population-based linked health administrative data. Cases were identified by either one hospitalization or two outpatient physician billings within a 12-month period with a diagnosis of non-affective psychosis. We estimated the cumulative incidence and EPI-treated incidence of non-affective psychosis using denominator data from the census. We also estimated the incidence of first-episode psychosis (people who would meet the case definition for an EPI program) using a novel approach.ResultsOur case definition identified 3245 cases of incident non-affective psychosis over the 17-year period. We estimate that the incidence of first-episode non-affective psychosis in the program catchment area is 33.3 per 100 000 per year (95% CI 31.4–35.1), which is more than twice as high as the EPI-treated incidence of 18.8 per 100 000 per year (95% CI 17.4–20.3).ConclusionsCase ascertainment strategies limited to specialized psychiatric services may substantially underestimate the incidence of non-affective psychotic disorders, relative to population-based estimates. Accurate information on the epidemiology of first-episode psychosis will enable us to more effectively resource EPI services and evaluate their coverage.

Download Full-text

VARIATION IN GREY MATTER VOLUME WITH DEGREE OF INSIGHT IN FIRST EPISODE PSYCHOSIS AND CHRONIC SCHIZOPHRENIA

Schizophrenia Research ◽

10.1016/j.schres.2010.02.589 ◽

2010 ◽

Vol 117 (2-3) ◽

pp. 340

Author(s):

J. McFarland ◽

D. Cannon ◽

H. Schmidt ◽

M. Ahmed ◽

S. Hehir ◽

...

Keyword(s):

Grey Matter ◽

Chronic Schizophrenia ◽

First Episode Psychosis ◽

First Episode ◽

Grey Matter Volume ◽

Matter Volume ◽

Episode Psychosis

Download Full-text

Is cognitive performance associated with anxiety and depression in first-episode psychosis?

Journal of Affective Disorders ◽

10.1016/j.jad.2019.11.161 ◽

2020 ◽

Vol 263 ◽

pp. 221-227 ◽

Cited By ~ 2

Author(s):

Maija Lindgren ◽

Heli Birling ◽

Tuula Kieseppä ◽

Annamari Tuulio-Henriksson

Keyword(s):

Cognitive Performance ◽

First Episode Psychosis ◽

Anxiety And Depression ◽

First Episode ◽

Episode Psychosis

Download Full-text

O5.1. GREY MATTER BRAIN CHANGES IN MEDICATED AND UNMEDICATED FIRST EPISODE PSYCHOSIS: A RANDOMISED PLACEBO-CONTROLLED TRIAL

Schizophrenia Bulletin ◽

10.1093/schbul/sbz021.209 ◽

2019 ◽

Vol 45 (Supplement_2) ◽

pp. S172-S173

Author(s):

Sidhant Chopra ◽

Alex Fornito ◽

Shona Francey ◽

Brian O’Donoghue ◽

Barnaby Nelson ◽

...

Keyword(s):

Grey Matter ◽

Controlled Trial ◽

First Episode Psychosis ◽

First Episode ◽

Episode Psychosis ◽

Brain Changes

Download Full-text

Paliperidone palmitate log-acting injection in patients with psychotic active clinic: start, change or increase of dose

European Psychiatry ◽

10.1016/j.eurpsy.2016.01.634 ◽

2016 ◽

Vol 33 (S1) ◽

pp. s249-s250

Author(s):

A.L. Gonzalez Galdamez ◽

M.D. Piqueras Acevedo ◽

M.R. Raposo Hernández ◽

I. Martínez Pérez ◽

P. Manzur Rojas ◽

...

Keyword(s):

Acute Exacerbation ◽

Descriptive Study ◽

First Episode Psychosis ◽

Paliperidone Palmitate ◽

First Episode ◽

Antipsychotic Treatment ◽

Early Stages ◽

Episode Psychosis ◽

Competing Interest ◽

Long Acting

The aim is to describe the experience of treatment with Paliperidone Palmitate long acting injection (PP) in patients with psychotic active clinic, whether diagnoses with schizophrenia or in patients with the first episode psychosis, as well as to reflect the improvement in the control of the symptoms that the patients can improve increasing the dose.MethodsWe have done a descriptive study of 34 patients hospitalized in psychiatry between January and July 2015 for psychotic active clinic who started treatment with PP or the previous dose was increased.Results91.2% of patients admitted for acute exacerbation of their usual pathology and 8.8% for a first episode psychosis. In the CGI scale, all the patients admitted scored as severe or markedly ill; going mostly mildly ill at discharge. For 55.9% of patients, the treatment was changed to PP, 29.4% of the dose was increased PP and 14.7% antipsychotic treatment was started with PP. Among patients change treatment, the main reason was non-adherence (47.4%). 70.6% of our patients were discharged with PP as only antipsychotic and 29.4% which was discharged with another antipsychotic, the most frequent association was of PP with Quetiapine (80%).ConclusionsPP is a highly effective medicament in the treatment of the schizophrenia that improves the adherence to the treatment, so in our experience and we consider it a medicament to be considered in the early stages of the disease. According to our experience and there are patients who can benefit from better control of symptoms adjusting the dose individually.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text